pseudoephedrine/loratadine (Alavert Allergy and Sinus D, Claritin D, ChlorTripolon, Alavert D-12, Claritin D-24 Hour)
Classes: Antihistamine/Decongestant Combos
Dosing and uses of Alavert Allergy and Sinus D, Claritin D (pseudoephedrine/loratadine)
Adult dosage forms and strengths
pseudoephedrine/loratadine
tablet, extended release
- 5mg/120mg
- 10mg/240mg
Allergic Rhinitis/Nasal Congestion
Immediate release: 1 tablet PO q12hr
Extended release: 1 tablet PO qd
Administration
Tablet should be swallowed whole & not broken, dissolved or chewed
Claritin-D extended release to be taken with a full glass of water
Other Indications & Uses
Perennial & seasonal allergic & vasomotor rhinitis, relief of symptoms from colds, urticaria, angioedema, anaphylactic reactions, pruritus, allergic conjunctivitis
Pediatric dosage forms and strengths
pseudoephedrine/loratadine
tablet, extended release
- 5mg/120mg
- 10mg/240mg
Allergic Rhinitis/Nasal Congestion
<12 years old
- Safety & efficacy not established
>12 years old
- Immediate release: 1 tablet PO q12hr
- Extended release: 1 tablet PO qD
Warnings
Contraindications
Documented hypersensitivity
Lower respiratory disease, eg, asthma (controversial)
Preemies & neonates
Nursing women
Concurrent or within 2 wk of MAO inhibitor use
Hepatic impairment
Cautions
Renal impairment, heart disease, BPH, hypertension, diabetes, glaucoma
Pregnancy/lactation
Pregnancy and lactation
Pregnancy category: B
Lactation: both drugs pass into breast milk, pseuoephedrine is concentrated in breast milk; use caution
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.